00:13 , Nov 22, 2017 |  BC Extra  |  Preclinical News

Functional assay helps predict patient response to MM therapies

In a study published in...
21:30 , Nov 16, 2017 |  BC Innovations  |  Tools & Techniques

Internal logic

Instead of designing T cells to fight cancer, an MIT group is using synthetic biology to directly manipulate the tumor cells and make them more immunogenic. The big advantage, says the team, is that the...
22:54 , Sep 14, 2017 |  BC Innovations  |  Targets & Mechanisms

Platelets YAP at cancer

While elevated platelet levels often signify an underlying malignancy, the molecular mechanisms linking the two are not well understood. Now, a team from MD Anderson has shown a well-known, but barely exploited signaling pathway mediates...
02:10 , Feb 14, 2017 |  BioCentury  |  Emerging Company Profile

Divide or conquer

Argonaut Therapeutics Ltd. is attacking cancer by inhibiting an epigenetic regulatory protein that controls a dual role for the E2F1 pathway. By inhibiting the PRMT5 enzyme, the company’s molecules flip the pathway from growth and...
07:00 , Jul 25, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Melanoma E2F transcription factor 1 (E2F1); tumor protein p73 (TP73; p73) Cell culture and mouse studies suggest combining methotrexate with an antifolate prodrug could help...
07:00 , Mar 12, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Retinoblastoma 1 (RB1; pRB) In vitro and mouse studies suggest that RB1 could help treat cancer by improving responses to...
08:00 , Jan 5, 2009 |  BC Week In Review  |  Company News

ArQule, Daiichi Sankyo, Roche deal

ArQule and Daiichi signed their previously announced deal to co-develop and co-market ArQule's ARQ 197 to treat cancer (see BioCentury, Nov. 17, 2008). Separately, Roche declined to exercise its option under a 2004 deal to...
07:00 , Sep 25, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Colorectal cancer E2F transcription factor 1 (E2F1); cyclin-dependent kinase 8 (CDK8); b-catenin Studies in flies and in human cell culture...
07:00 , Sep 25, 2008 |  BC Innovations  |  Targets & Mechanisms

CDK8 is Enough in Colorectal Cancer

Of the 11 known cyclin-dependent kinases, about half have long been the focus of cancer drug developers because they are involved in controlling cell-cycle progression, which goes into overdrive in cancer. However, none of the...
07:00 , Apr 21, 2008 |  BC Week In Review  |  Clinical News

ARQ 761: Phase I start

This year, ArQule will begin a U.S. Phase I trial of IV ARQ 761. Roche has an option to license worldwide rights to ArQule's E2F transcription factor 1 (E2F1) program after Phase II testing. ArQule...